Nunzia Pharmaceutical Corporation
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Com… Read more
Nunzia Pharmaceutical Corporation (NUNZ) - Net Assets
Latest net assets as of September 2022: $-191.32K USD
Based on the latest financial reports, Nunzia Pharmaceutical Corporation (NUNZ) has net assets worth $-191.32K USD as of September 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($35.37K) and total liabilities ($226.69K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-191.32K |
| % of Total Assets | -540.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Nunzia Pharmaceutical Corporation - Net Assets Trend (2004–2021)
This chart illustrates how Nunzia Pharmaceutical Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nunzia Pharmaceutical Corporation (2004–2021)
The table below shows the annual net assets of Nunzia Pharmaceutical Corporation from 2004 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | $-94.17K | -158.69% |
| 2020-12-31 | $-36.40K | -61.26% |
| 2019-12-31 | $-22.57K | +92.32% |
| 2018-12-31 | $-293.97K | -9.12% |
| 2017-12-31 | $-269.39K | -100.02% |
| 2010-12-31 | $1.48 Billion | +39759.65% |
| 2008-12-31 | $-3.73 Million | -3.73% |
| 2007-12-31 | $-3.59 Million | -3.57% |
| 2006-12-31 | $-3.47 Million | -3.43% |
| 2005-12-31 | $-3.35 Million | -6.27% |
| 2004-12-31 | $-3.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nunzia Pharmaceutical Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14217512900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $434.17K | % |
| Other Comprehensive Income | $31.65K | % |
| Other Components | $178.85 Million | % |
| Total Equity | $-94.17K | 100.00% |
Nunzia Pharmaceutical Corporation Competitors by Market Cap
The table below lists competitors of Nunzia Pharmaceutical Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OMNIA HOLD (OHZ.SG)
STU:OHZ
|
$43.47K |
|
Bruton Limited
OL:BRUT
|
$43.50K |
|
Pomvom
TA:PMVM
|
$43.54K |
|
Trillium Acquisition Corp
V:TCK-P
|
$43.55K |
|
BRIGHTSPIRE CAP. CL.A-01
F:41W0
|
$43.43K |
|
PRESS CORPORATION LIMITED
MSE:PCL
|
$43.42K |
|
Ashtead Technology Holdings PLC
LSE:AT
|
$43.41K |
|
LIBERTY INT QVC-A (LB3A.SG)
STU:LB3A
|
$43.40K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nunzia Pharmaceutical Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from -36,404 to -94,174, a change of -57,770.
- Net loss of 78,064,632 reduced equity.
- Other comprehensive income increased equity by 31,649.
- Other factors increased equity by 77,975,213.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-78.06 Million | -82894.04% |
| Other Comprehensive Income | $31.65K | +33.61% |
| Other Changes | $77.98 Million | +82799.09% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Nunzia Pharmaceutical Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-196.35 | $0.00 | x |
| 2005-12-31 | $-208.49 | $0.00 | x |
| 2006-12-31 | $-215.64 | $0.00 | x |
| 2007-12-31 | $-223.35 | $0.00 | x |
| 2008-12-31 | $-231.68 | $0.00 | x |
| 2009-12-31 | $-2412.57 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nunzia Pharmaceutical Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-159.40K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $9.40K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $183.90K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $211.30K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $322.70K |
| 2010 | 0.02% | 0.00% | 0.00x | 1.00x | $-147.54 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-298.46K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $10.82K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.38K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.01 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-78.06 Million |
Industry Comparison
This section compares Nunzia Pharmaceutical Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nunzia Pharmaceutical Corporation (NUNZ) | $-191.32K | 0.00% | N/A | $43.45K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |